0001127602-22-028239.txt : 20221223
0001127602-22-028239.hdr.sgml : 20221223
20221223161535
ACCESSION NUMBER: 0001127602-22-028239
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220425
FILED AS OF DATE: 20221223
DATE AS OF CHANGE: 20221223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eisele Jeffrey
CENTRAL INDEX KEY: 0001827326
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 221485554
MAIL ADDRESS:
STREET 1: APELLIS PHARMACEUTICALS, INC.
STREET 2: 100 5TH AVENUE, 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-04-25
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001827326
Eisele Jeffrey
C/O APELLIS PHARMACEUTICALS, INC.
WALTHAM
MA
02451
1
Exec VP, Program Team Lead
Common Stock
2022-04-25
4
J
0
1250
0
D
31739
D
Common Stock
2022-12-22
4
F
0
89
51.68
D
31650
D
This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
This represents shares used to cover tax withholding on a Restricted Stock Unit release.
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
2022-12-23